The Hidden IP Trap in Clinical Research: How Unvetted Software and AI Can Imperil Sponsor Patents
Clinical development is already a high-wire act—timelines, budgets, regulators, and scientific uncertainty. But there’s a quieter risk that’s increasingly…

The “Hard 20” in New Zealand Isn’t Just a Patent Rule—it’s a Business Model.
In New Zealand, the clock doesn’t merely tick on drug patents. It dictates how generics are financed, timed, and launched—and it can turn a promising pipeline into a dead end …

Most people in pharma think they understand “patent dates.” They don’t.
If you work in drug development, regulatory strategy, or commercial planning, you’ve probably seen it: a spreadsheet with a clean-looking “patent expiry” date—followed by a scram…

Pharma is built on patents—but the real battleground is often the tax treatment of those patents.
That’s the uncomfortable truth behind the “patent box” conversation. In plain terms, a patent box is a tax strategy designed to reduce the tax burden on i…

180 Days: The Generic Launch Window That Can Make (or Break) Your Entire Year
In generic pharma, timing isn’t just a schedule—it’s strategy, leverage, and risk management.
There’s a reason the industry still treats the “180-day exclusivity” period like…

Europe’s “divisional patent” trap is one of those legal mechanisms that sounds technical—until you see what it does to real-world patients, pricing, and competition.
Here’s the core problem: Big Pharma can use Europe’s divisional patent system to delay…

Biopharma is in a talent crunch—and it’s showing up in the most unglamorous place: the handoff between IP and pipeline.
If you’re building a patent-to-pipeline strategy, you already know the timeline is unforgiving. But what many teams still underestim…

Russia’s biosimilar story is no longer a footnote—it’s a playbook. And if you’re in pharma, biotech, or investing, you should treat it like one.
Here’s the agitation: while much of the West is focused on near-term patent cliffs, regulatory delays, and …

Pharma has a supply-chain problem—and patents may be the most underused early-warning system.
Drug shortages don’t usually announce themselves with a siren. They show up quietly: a delayed shipment, a sudden capacity constraint, a manufacturing change …

The drug patent clock is ticking—most IP teams are forecasting with the wrong instrument.
In pharma, timing isn’t a footnote. It’s the difference between a protected revenue stream and a sudden erosion event. Yet many IP teams, R&D strategists, and…